Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 16%: Here's What Analysts Think Will Happen Next
Chugai Pharmaceutical Co., Ltd. (TSE:4519) investors will be delighted, with the company turning in some strong numbers with its latest results. It was a positive result, with revenues and statutory earnings per share (EPS) both performing well. Revenues were 16% higher than the analysts had forecast, at JP¥405b, while EPS of JP¥87.20 beat analyst models by 9.2%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following the latest results, Chugai Pharmaceutical's 14 analysts are now forecasting revenues of JP¥1.52t in 2027. This would be a credible 7.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to ascend 15% to JP¥351. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥1.52t and earnings per share (EPS) of JP¥350 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
View our latest analysis for Chugai Pharmaceutical
There were no changes to revenue or earnings estimates or the price target of JP¥8,447, suggesting that the company has met expectations in its recent result. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Chugai Pharmaceutical analyst has a price target of JP¥11,000 per share, while the most pessimistic values it at JP¥6,100. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Chugai Pharmaceutical's growth to accelerate, with the forecast 6.0% annualised growth to the end of 2027 ranking favourably alongside historical growth of 4.0% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.7% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Chugai Pharmaceutical is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Chugai Pharmaceutical analysts - going out to 2028, and you can see them free on our platform here.
It is also worth noting that we have found 1 warning sign for Chugai Pharmaceutical that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.